Cancer-focused AVEO Pharmaceuticals Inc.'s rare balance between antibody and small-molecule discovery bagged $53 million in a Series D financing that leaves the firm with enough cash to last "a little bit short of two years," said Tuan Ha-Ngoc, president and CEO. (BioWorld Today)